BioPharmSignal logoBioPharmSignal

Biotech News

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals (RYTM)Rhythm PharmaceuticalsCommercial

-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome --

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive guidance for IMCIVREE ® (setmelanotide) to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS).

Related news

RYTMRhythm Pharmaceuticals2026-10-13 23:30 EST

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

RYTMRhythm Pharmaceuticals2026-08-17 12:00 EST

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-11-02 21:02 EST

CVRx to Participate in Upcoming Investor Conferences

MLYSMineralys Therapeutics2026-10-19 20:05 EST

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

BLTEBelite Bio2026-08-24 20:00 EST

Belite Bio to Host Virtual Commercial Day on September 2, 2026

MISTMilestone Pharmaceuticals Inc.2026-09-24 12:00 EST

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

LXRXLexicon Pharmaceuticals2026-10-29 12:30 EST

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

View all latest news

Rhythm Pharmaceuticals

Rare Neuroendocrine Diseases Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine disorders characterized by pathological hunger and severe obesity. Its programs focus on restoring melanocortin-4 receptor pathway signaling in genetically or structurally defined patient populations. IMCIVREE...

Recent company news

RYTMRhythm Pharmaceuticals2026-11-04 13:00 EST

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

RYTMRhythm Pharmaceuticals2026-11-03 12:00 EST

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

RYTMRhythm Pharmaceuticals2026-11-03 02:59 EST

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

RYTMRhythm Pharmaceuticals2026-10-13 23:30 EST

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Stock data

Close
105.02 USD
Market cap
5.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States